Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/20/17 → 9/20/20 |
Funding
- INC Research, LLC (Prot #2215-CL-9100)
- Astellas Pharma Global Development, Inc. (Prot #2215-CL-9100)
Prot #2215-CL-9100: A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3 Mutated AML in Complete Remission (CR) with M
- Frankfurt, Olga (PD/PI)
Project: Research project